Bristol-Myers Squibb Completes €5 Billion Note Offering

Bristol-Myers Squibb ( (BMY) ) has shared an update.

On November 10, 2025, BMS Ireland Capital Funding, a subsidiary of Bristol-Myers Squibb, completed a public offering of €5 billion in senior unsecured notes with varying maturities and interest rates. The proceeds, along with $3 billion in cash, will be used for a tender offer to purchase outstanding notes and for general corporate purposes, potentially impacting the company’s financial strategy and market positioning.

The most recent analyst rating on (BMY) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Bristol-Myers Squibb stock, see the BMY Stock Forecast page.

Spark’s Take on BMY Stock

According to Spark, TipRanks’ AI Analyst, BMY is a Neutral.

Bristol-Myers Squibb’s strong earnings call and solid valuation metrics are the most significant factors driving the score. Financial performance is robust but tempered by high debt levels. Technical indicators suggest caution with potential bearish momentum.

To see Spark’s full report on BMY stock, click here.

More about Bristol-Myers Squibb

Bristol-Myers Squibb Company operates in the pharmaceutical industry, focusing on the development and commercialization of innovative medicines. The company is known for its work in oncology, immunology, cardiovascular, and fibrotic diseases, serving a global market.

Average Trading Volume: 14,560,920

Technical Sentiment Signal: Sell

Current Market Cap: $95.05B

For an in-depth examination of BMY stock, go to TipRanks’ Overview page.